Hai Zheng Pharmaceutical introduced the first innovative small molecule conjugate drug.

On September 17th, Haisco Pharmaceutical announced its partnership with Shenzhen Aixinda Wei Pharmaceutical Technology Co., Ltd. Haisco Pharmaceutical will introduce the rights to the targeted small molecule conjugate drug HSE-001 in the collaborative region. HSE-001 is the first small molecule conjugate drug with potential global first-in-class characteristics introduced by Haisco Pharmaceutical. In addition, Haisco Pharmaceutical and Aixinda Wei will also jointly promote more new drug development based on the targeted small molecule conjugate drug technology platform activated by AKR1C3 enzyme.